NEW YORK, Aug. 17, 2023 /PRNewswire/ -- TFC Therapeutics (TFC), a biotechnology company focused on developing novel biologics to target and eliminate key drivers of cancer recurrence and metastasis, today announced a financing led by ARCH Venture Partners with participation from Breakout Ventures, Alexandria Real Estate Equities, and Alumni Ventures. In connection with the financing, Steven Gillis, Ph.D., Managing Director at ARCH, has been appointed as Chairman of the TFC Board of Directors.